Skip to Main Content

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and refreshing because … you know what we will say … that oh-so-predictable routine of meetings, deadlines, and what-not has returned. The world, after all, keeps spinning, so no point in trying to push back. Instead, join us for a cup of stimulation, since the neurons can use all the help they can get. So time to dig in, yes? Here are some tidbits to help you on your journey. Hope you conquer the world and do keep in touch …

More than a dozen countries around the world are taking steps to restrict or ban sales of Zantac and other heartburn medicines containing high levels of a carcinogen, underscoring mounting concern about the quality of the global pharmaceutical supply chain, STAT writes. Over the past three days, Switzerland, Cyprus, and Egypt became the latest to ban all such medicines after traces of NDMA were detected. Last week, Health Canada asked manufacturers to halt shipments, although the agency stopped short of demanding recalls. Novartis (NVS), however, has recalled its heartburn pill globally. The FDA and the European Medicines Agency have already begun reviews.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.